These reports demonstrate that avasimibe markedly inhibited tumor growth in vivo by targeting the downstream targets, such as Sterol O-Acyltransferase 1 (SOAT1) (8) and Acetyl-CoA Acetyltransferase 1 (ACAT-1) (11). Here, ACAT1 is linked to neoplasm.